- Source: Rezafungin
Rezafungin, sold under the brand name Rezzayo (by Melinta Therapeutics), is a medication used for the treatment of invasive candidiasis. It is an echinocandin antifungal.
https://rezzayo.com/
Rezafungin was approved for medical use in the United States in March 2023, and in the European Union in December 2023.
Medical uses
In the United States, rezafungin is indicated indicated in adults who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
In the European Union, rezafungin is indicated for the treatment of invasive candidiasis in adults.
Society and culture
= Legal status
=Rezafungin was approved for medical use in the United States in March 2023, The FDA granted the application for rezafungin orphan drug, fast track, and priority review designations.
In October 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rezzayo, intended for the treatment of invasive candidiasis in adults. The applicant for this medicinal product is Mundipharma GmbH. Rezafungin was approved for medical use in the European Union in December 2023.
= Brand names
=Rezafungin is the international nonproprietary name.
Rezafungin is sold under the brand name Rezzayo.
References
External links
"Rezafungin Injection". U.S. Food and Drug Administration. 18 April 2023.
Kata Kunci Pencarian:
- Rezafungin
- ATC code J02
- Echinocandin
- List of drugs: Re
- Antifungal
- Fosmanogepix
- Antimicrobial resistance
- Melinta Therapeutics
